Q1 Earnings Forecast for Immunome Issued By Leerink Partnrs

Immunome, Inc. (NASDAQ:IMNM) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Immunome in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will earn ($0.94) per share for the quarter. The consensus estimate for Immunome’s current full-year earnings is ($2.21) per share. Leerink Partnrs also issued estimates for Immunome’s Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($1.02) EPS, Q4 2025 earnings at ($1.07) EPS, FY2025 earnings at ($4.06) EPS, FY2026 earnings at ($4.17) EPS and FY2027 earnings at ($3.80) EPS.

Several other analysts have also commented on IMNM. Piper Sandler lowered their price objective on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price target on shares of Immunome in a report on Monday, January 13th. Finally, Stephens initiated coverage on Immunome in a report on Friday, November 8th. They set an “overweight” rating and a $30.00 price objective for the company. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $28.60.

Immunome Price Performance

NASDAQ IMNM opened at $10.27 on Monday. The stock has a market capitalization of $819.34 million, a price-to-earnings ratio of -1.27 and a beta of 1.90. The business’s fifty day moving average is $11.09 and its 200-day moving average is $12.52. Immunome has a one year low of $8.97 and a one year high of $30.96.

Insider Activity at Immunome

In other news, CTO Philip Tsai purchased 21,000 shares of the stock in a transaction dated Thursday, November 21st. The shares were purchased at an average cost of $9.43 per share, with a total value of $198,030.00. Following the completion of the acquisition, the chief technology officer now owns 21,000 shares in the company, valued at $198,030. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Clay B. Siegall acquired 66,057 shares of the business’s stock in a transaction dated Thursday, November 21st. The stock was purchased at an average price of $9.54 per share, with a total value of $630,183.78. Following the completion of the transaction, the chief executive officer now directly owns 485,693 shares of the company’s stock, valued at $4,633,511.22. This trade represents a 15.74 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 252,862 shares of company stock worth $2,140,545. 8.60% of the stock is owned by corporate insiders.

Institutional Trading of Immunome

Several institutional investors and hedge funds have recently bought and sold shares of IMNM. JPMorgan Chase & Co. grew its holdings in shares of Immunome by 6.6% during the third quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company’s stock worth $359,000 after purchasing an additional 1,520 shares in the last quarter. Sequoia Financial Advisors LLC grew its stake in Immunome by 11.7% in the 4th quarter. Sequoia Financial Advisors LLC now owns 19,065 shares of the company’s stock worth $202,000 after buying an additional 2,000 shares in the last quarter. Intech Investment Management LLC increased its holdings in shares of Immunome by 26.5% in the 4th quarter. Intech Investment Management LLC now owns 18,961 shares of the company’s stock worth $201,000 after buying an additional 3,974 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Immunome by 34.6% during the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after buying an additional 4,129 shares in the last quarter. Finally, Cerity Partners LLC lifted its holdings in shares of Immunome by 10.5% during the 3rd quarter. Cerity Partners LLC now owns 53,103 shares of the company’s stock worth $776,000 after acquiring an additional 5,043 shares during the last quarter. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.